Category Archives: Pharmacogenomics

Study Demonstrates Superior Performance of ThyGeNEXT and ThyraMIR vs. Other Molecular Tests

PARSIPPANY, NJ, Oct. 26, 2020 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (NASDAQ: IDXG) announced today that the study entitled Multiplatform molecular test performance in indeterminate thyroid nodules was published on-line in the peer-reviewed journal, Diagnostic Cytopathology. This paper represents the culmination of a multi-center, blinded clinical validation study in which gold standard unanimous histopathology consensus diagnosis was utilized. The study results demonstrate that ThyGeNEXT + ThyraMIR combination testing yield the highest positive predictive value (PPV) and similar negative predictive value (NPV) in comparison to other marketed tests for the same indication.

Approximately 25% of thyroid nodule fine needle aspirates (FNAs) have cytology that is indeterminate for malignant disease. Ancillary multiplatform testing with ThyGeNEXT and ThyraMIR assists in the accurate risk stratification of these FNAs, ultimately helping to distinguish patients who are more likely to benefit from conservative management from those who are more likely to benefit from surgical intervention.

The published manuscript is the first to report the performance characteristics of combination ThyGeNEXT and ThyraMIR testing in a blinded multicenter study. ThyGeNEXT is the companys most recent next generation sequencing based test that was expanded from its original version (ThyGenX) to include markers that have targeted therapies and those that can identify aggressive forms of thyroid cancer. The study demonstrates that combination testing with ThyGeNEXT and ThyraMIR has both high sensitivity (95%) and high specificity (90%) for identifying disease. It also highlights the important role that ThyraMIRthe companys proprietary microRNA risk classifiercan play in helping to identify malignancy in nodules where single platform mutation panels commonly detect mutations that by themselves have suboptimal PPV for malignancy.

According to Jack Stover, President and CEO of Interpace, The results of this independent study reported in a well-respected journal reflect the strong clinical performance and overall value of our combined thyroid assays in helping physicians manage their patients with potential thyroid cancer.

About ThyGeNEXT and ThyraMIR

ThyGeNEXT is Interpaces most recent next generation sequencing test that was expanded from its original version (ThyGenX) to include markers that have targeted therapies and those that can identify aggressive forms of thyroid cancer.

ThyGeNEXT utilizes state-of-the-art next-generation sequencing (NGS) to identify more than 100 genetic alterations associated with papillary and follicular thyroid carcinomas, the two most common forms of thyroid cancer, as well as Medullary Thyroid Carcinoma. ThyraMIR is the first microRNA gene expression classifier. MicroRNAs are small, non-coding RNAs that bind to messenger RNA and regulate expression of genes involved in human cancers, including every subtype of thyroid cancer. ThyraMIR measures the expression of 10 microRNAs. Both ThyGeNEXT and ThyraMIR are covered by Medicare and most Commercial insurers.

According to the American Thyroid Association, approximately 20% of the 525,000 thyroid fine needle aspirations (FNAs) performed on an annual basis in the U.S. are indeterminate for malignancy based on standard cytological evaluation, and thus are candidates for ThyGeNEXT and ThyraMIR.

ThyGeNEXT and ThyraMIR reflex testing yields high predictive value in determining the presence and absence of cancer in thyroid nodules. The combination of both tests can improve risk stratification and surgical decision-making when standard cytopathology does not provide a clear diagnosis.

About Interpace Biosciences

Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.

Clinical services, through Interpace Diagnostics, provides clinically useful molecular diagnostic tests, bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has four commercialized molecular tests and one test in a clinical evaluation process (CEP): PancraGEN for the diagnosis and prognosis of pancreatic cancer from pancreatic cysts; ThyGeNEXT for the diagnosis of thyroid cancer from thyroid nodules utilizing a next generation sequencing assay; ThyraMIR for the diagnosis of thyroid cancer from thyroid nodules utilizing a proprietary gene expression assay; and RespriDX that differentiates lung cancer of primary vs. metastatic origin. In addition, BarreGEN for Barretts Esophagus, is currently in a clinical evaluation program whereby we gather information from physicians using BarreGEN to assist us in positioning the product for full launch, partnering and potentially supporting reimbursement with payers.

Pharma services, through Interpace Pharma Solutions, provides pharmacogenomics testing, genotyping, biorepository and other customized services to the pharmaceutical and biotech industries. Pharma services also advance personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs with the goals of delivering safer, more effective drugs to market more quickly, and improving patient care.

For more information, please visit Interpace Biosciences website at http://www.interpace.com.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Companys future financial and operating performance. The Company has attempted to identify forward looking statements by terminology including believes, estimates, anticipates, expects, plans, projects, intends, potential, may, could, might, will, should, approximately or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Companys control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Companys actual results to be materially different from those expressed or implied by any forward-looking statement. Additionally, all forward-looking statements are subject to the Risk Factors detailed from time to time in the Companys most recent Annual Report on Form 10-K filed on April 22, 2020, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

Contacts: Investor RelationsEdison Group Joseph Green/ Megan Paul(646) 653-7030 / 7034jgreen@edisongroup.com/ mpaul@edisongroup.com

Read the original post:
Interpace Biosciences Announces Results of Seminal Clinical Validation Study for Thyroid Assays - GlobeNewswire

The global gene amplification technologies market is poised for growth on the back of rising demand for genetic information for identifying and mapping all the genes of human genome. The market is slated to reach a valuation of US$2.2 bn in 2017.

View Report :https://www.transparencymarketresearch.com/gene-amplification-technologies-market.html

The report presents the latest technological developments in the field and a growth map for the coming years. It also explains its effect on market dynamics and leverages SWOT analysis of major industry segments

Gene Amplification Technologies Market: Trends and Opportunities

The single-most important growth driver for gene amplification technologies market has been the Human Genome Projects (HGP). It is an international, collaborative research effort to sequence all the chemical base pairs that form the DNA of the speciesHomo sapiens. Another major growth driver is molecular diagnostics that helps uncover specific sequences in DNA or RNA to check if they are associated with any disease. It is clinically used for oncology, coagulation, genetic disease screening, infectious diseases, pharmacogenomics, and human leukocyte antigen typing. Development in clinical diagnostic tools, is also expected to boost the growth of the gene amplification technologies market.

Get Brochure of the Report @https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=426

Other factors driving the gene amplification technologiesmarket are the increasing focus on research and development in the field of molecular diagnostics, drug discovery, genetic testing, toxicology, environmental monitoring, animal husbandry, bioremediation, forensics, and quality control in the food industry. Gene amplification technologies, however, are expensive to develop. This has, to some degree, served to counter the growth of the market.

Gene Amplification Technologies Market: Technology and Application-wise Segmentation

There are various ways in which the gene amplification technologies market can be segmented. For example, based on technology, it can be divided into the following: Isothermal DNA amplification, target amplification,cycling temperature DNA amplification, isothermal signal amplification, linear gene amplification, cycling temperature signal gene amplification, and exponential gene amplification.By application, the market can be divided into identity, forensics, identity, paternity, food safety, medical, veterinary, and agri-diagnostics. Medical and forensics are the two largest segments in terms of application.

REQUEST FOR COVID19 IMPACT ANALYSIS https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=426

Gene Amplification Technologies Market: Region-wise Outlook

Geographically the market for gene amplification technologies can be divided into Europe, Asia Pacific, North America, Latin America, and Middle East and Africa. North America has exhibited stellar growth so far, with maximum revenue raked in. This has been possible on account of high allocations for healthcare infrastructure, and research and development for genetic testing, diagnostics and detection of critical diseases all of which have yielded unprecedented technological advancements. North America is expected to remain the leading market in the upcoming years too, because of continued government funding of research and infrastructure.

Asia Pacific would also put up a good showing, it is predicted. This is mainly due to governments of various nations in the region increasingly focusing on upgrading healthcare infrastructure. Fast developing economies such as China and India are expected to see higher growth rates because of increased abundant manpower of skilled workers who can carry out proper research, lower cost, and supportive government policies.

Read our Case study at :https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

Players in the Gene Amplification Technologies Market

Some of the leading entities in the gene amplification technologies market that have been profiled in the report are: Chugai Biopharmaceuticals Inc., Abbott Laboratories, Cepheid, Agilent Technologies, ID Biomedical Corporation, Molecular Sensing PLC, Orchid Biosciences Inc., Rubicon Genomics, and U.S. Genomics.

More Trending Reports by Transparency Market Research 1.http://www.prnewswire.com/news-releases/thrust-on-pharmaceutical-sector-to-develop-novel-drugs-for-clinical-conditions-propels-pharmaceutical-excipients-market-transparency-market-research-301017102.html

2.https://www.biospace.com/article/electrophysiology-devices-market-rising-incidences-of-cardiac-arrhythmias-expected-to-propel-the-market/

Read the original here:
Gene Amplification Technologies Market Trends by Manufacturers, States, Type and Application, Forecast to 2016 2024 - The Think Curiouser

The birth of the "genomic era" is marked by the completion of the Human Genome Project in 2003, whereby next-generation sequencing whittled down the complexity of a human being to a code of letters. Advances in high-throughput technologies have added further data, exploring the interactions between genes and the environment and vice versa.

As our knowledge of life at the molecular level continues to evolve, it becomes increasingly apparent that, to effectively understand and manage human health, a shift from a one-size-fits-all approach to focusing on humans at the individual level is required. We're already seeing the "promise" of personalized medicine being delivered in areas such as pharmacogenomics and cancer immunotherapy, but the insights garnered from omic sciences such as metabolomics are also impacting the way we think about nutrition.

A number of noncommunicable diseases are linked to nutrition, including diabetes, cancer and cardiovascular disease. A variety of different dietary interventions have been proposed for the prevention and treatment of such diseases as an alternative to pharmacological medication. But we now know that individual differences in our biochemistry, metabolism and genetics all impact our response to nutrition, and prescribing the same intervention broadly will not produce the same result for each unique patient.

So how do we use the information obtained from metabolomics approaches to move towards personalized nutrition? That's the focus of this interview with Professor Lorraine Brennan, Conway Fellow and principal investigator at the University College Dublin Institute of Food and Health where she leads the Nutrition, Biomarkers and Health research group.

Molly Campbell (MC): Why is it important that humans move towards a personalized nutrition approach, as opposed to a "one-size-fits-all" approach?Lorraine Brennan (LB): The realization that there are huge inter-individual responses to dietary interventions is pushing us to re-think our concepts. While dietary recommendations may be a good diet for all, they may not represent the optimal diet for all. To take into account the individual, we have to start understanding individual responses and metabolomics has huge potential in this regard. The emergence of precision nutrition will help pave the way forward for the development of more tailored dietary advice.MC: In your opinion, what have been some of the most exciting developments in metabolomics and nutrition research over the past few years?LB: Metabolomics has had a major impact in nutrition research. The whole area of dietary biomarkers has completely evolved as a result of developments in metabolomics. In particular, there is growing interest in the use of objective biomarkers of food intake and metabolomics offers a route into the identification and development of novel biomarkers. The further development of these biomarkers should allow us to develop more accurate methods for assessment of food intake. With respect to understanding the mechanisms underpinning the health benefits of certain diets metabolomics has played a key role both in intervention studies and also in epidemiology studies. Continued expansion of the metabolome coverage offers great opportunities for nutrition research.MC: Your laboratory focuses on the development of metabolomics for nutritional research. Can you please tell us about your key focus points within this field?LB: I have a large program of research focussed on the identification, development and use of food intake biomarkers. One of the key challenges we face in the field of human nutrition is our poor ability to assess dietary intake. Our current methods have a number of well-established limitations and food intake biomarkers offer a new and objective approach. We are working on development of new biomarkers and also on working out how to use such biomarkers in nutrition research. We are also working on precision nutrition and new methods for delivering personalized dietary advice to individuals.

MC: You recently published a review paper outlining metabotyping and its role in nutrition research. Please can you tell us more about metabotypes what they are and how they can be used to identify an individual's response to a dietary intervention?

LB: Metabotypes are groups of individuals defined on the basis of their similarities in metabolic profile, which in turn results from an interaction between lifestyle, gut microbiome, genes and environmental factors. With respect to dietary interventions application of a metabotype approach has led to the identification of groups of subjects with distinct metabolic phenotypes/metabotypes and unique responses. The metabotype approach represents a tool through which we can start to understand individual responses to interventions, with the ultimate goal being to employ it for the delivery of personalized nutrition.

MC: What key technologies do you utilize in your lab? Are there any challenges that come with using such methods?

LB: We use nuclear magnetic resonance spectroscopy and mass spectrometry-based metabolomics approaches. We find that both approaches complement each other. One of the key challenges for us is metabolite identification. As we are interested in metabolites that originate in food, many of the metabolites we wish to identify are not present in databases. As a consequence, we put a huge effort into compound identification. I think that we need to work together as a community to improve this and make significant breakthroughs. Cross-lab collaborations could make significant advancements in this area.MC: In your opinion, what is the greatest barrier to introducing a personalized nutrition approach on a global scale?

LB: We are still building the evidence base for personalized nutrition. More research is needed to understand the responses to diet. The results to date are very encouraging, and more research is needed to define the optimal diet at an individual level.Professor Lorraine Brennan was speaking to Molly Campbell, Science Writer, Technology Networks.

More here:
What's Your (Metabo)Type? Metabolomics and the Pursuit of Personalized Nutrition - Technology Networks

The large scale Pharmacogenomics marketing report provides CAGR values along with its fluctuations for the specific forecast period. This persuasive marketing report has been generated by taking into thought several aspects of marketing research and analysis that can be listed as market size estimations, market dynamics, company & market best practices, entry level marketing strategies, positioning and segmentations, competitive landscaping, opportunity analysis, economic forecasting, industry-specific technology solutions, roadmap analysis, targeting key buying criteria & in-depth benchmarking of vendor offerings. This Pharmacogenomics market research report is of great importance for superior decision making and achieving competitive advantage.

Get FREE Sample PDF (including COVID19 Impact Analysis) of Market Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-pharmacogenomics-market&rp

Market Analysis and Insights: Global Pharmacogenomics Market

Global pharmacogenomics market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.

The major players covered in the globalpharmacogenomics marketareAbbott, AstraZeneca, Bayer AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc, OPKO Health, Inc, Teva Pharmaceutical Industries Ltd, Myriad Genetics, Inc., QIAGEN,OneOme, LLC, Illumina, Inc, Empire Genomics, LLC, and Dynamic DNA Laboratories among others.

The factors primarily driven the growth of pharmacogenomics market are high adoption of personalized therapy. In addition, high prevalence of life-threatening disorders globally and improvement in molecular techniques for developing pharmacogenomics-based therapeutics are some of the impacting factors for the growth of this market. Nevertheless, less trained expertise or technically skilled professionals and coupled with difficulties in terracing gene variation that significantly affects the drug response are the factors that hinder the growth of this market.

Pharmacogenomics is the study of how human genes affect the way bodies responds to the medications. It is emerging field which combines the pharmacology and genomics to develop highly effective and right or safe medicines tailored to the patients genetic makeup.

Pharmacogenomics market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Global Pharmacogenomics Market Scope and Market Size

Pharmacogenomics market is segmented on the basis of technology, application, end-users and distribution channel.

Pharmacogenomics Market Country Level Analysis

Pharmacogenomics market is analysed and market size information is provided by country, technology, application, end-users and distribution channel as referenced above.

The countries covered in the global pharmacogenomics market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, in the Asia-Pacific, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

North America has been witnessing a positive growth throughout the forecasted period due to the presence of refined healthcare expenditure and increased patient awareness level as well as preference personalized medicines. Europe is considered a second largest growing regional segment owing to the growing geriatric population and rising prevalence of chronic diseases.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Pharmacogenomics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Pharmacogenomics Market Share Analysis

Pharmacogenomics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies focus related to global pharmacogenomics market.

Customization Available: Global Pharmacogenomics Market

Data Bridge Market Researchis a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analysed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-pharmacogenomics-market&rp

About Data Bridge Market Research:

Data Bridge Market Researchis a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us :

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475Mail:Corporatesales@databridgemarketresearch.com

More:
Pharmacogenomics Market 2020-2027 Incredible Possibilities, Growth With Industry Study, Detailed Analysis || Leading Players Abbott, AstraZeneca,...

Genetic variation may mediate the increased risk of cardiovascular disease (CVD) in chemotherapy-treated testicular cancer (TC) patients compared to the general population. Involved single nucleotide polymorphisms (SNPs) might differ from known CVD-associated SNPs in the general population. We performed an explorative genome-wide association study (GWAS) in TC patients. TC patients treated with platinum-based chemotherapy between 1977 and 2011, age 55 years at diagnosis, and 3 years relapse-free follow-up were genotyped. Association between SNPs and CVD occurrence during treatment or follow-up was analyzed. Data-driven Expression Prioritized Integration for Complex Trait (DEPICT) provided insight into enriched gene sets, i.e., biological themes. During a median follow-up of 11 years (range 3-37), CVD occurred in 53 (14%) of 375 genotyped patients. Based on 179 SNPs associated at p0.001, 141 independent genomic loci associated with CVD occurrence. Subsequent, DEPICT found ten biological themes, with the RAC2/RAC3 network (linked to endothelial activation) as the most prominent theme. Biology of this network was illustrated in a TC cohort (n=60) by increased circulating endothelial cells during chemotherapy. In conclusion, the ten observed biological themes highlight possible pathways involved in CVD in chemotherapy-treated TC patients. Insight in the genetic susceptibility to CVD in TC patients can aid future intervention strategies.

The pharmacogenomics journal. 2020 Oct 03 [Epub ahead of print]

Lars C Steggink, Hink Boer, Coby Meijer, Joop D Lefrandt, Leon W M M Terstappen, Rudolf S N Fehrmann, Jourik A Gietema

Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., Department of Internal Medicine, Division of Vascular Medicine, University Medical Center Groningen, University of Groningen, Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands., Medical Cell BioPhysics, University of Twente, Drienerlolaan 5, 7522 NB, Enschede, The Netherlands., Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, Hanzeplein 1, 9713 GZ, Groningen, The Netherlands. .

PubMed http://www.ncbi.nlm.nih.gov/pubmed/33011741

Read the rest here:
Genome-wide association study of cardiovascular disease in testicular cancer patients treated with platinum-based chemotherapy. - UroToday

The analysis of GlobalPharmacogenomics Marketincludes market size, upstream situation, market segmentation, price & cost and industry environment. In addition, the report outlines the factors driving industry growth and the description of market channels. The report begins from overview of industrial chain structure, and describes the upstream. Besides, the report analyses market size and forecast in different geographies, type and end-use segment, in addition, the report introduces market competition overview among the major companies and companies profiles, besides, market price and channel features are covered in the report.

Feel free to contact us for any inquiry, Download PDF Sample Copy of Pharmacogenomics Market @https://www.supplydemandmarketresearch.com/home/contact/1508770?ref=Sample-and-Brochure&toccode=SDMRHE1508770

According toSupply demand Market Research, ThePharmacogenomics MarketMarket 2020 Research offers an extensive analysis of key drivers, leading market players, key segments, and regions. Besides this, the experts have deeply studied different geographical areas and presented a competitive scenario to assist new entrants, leading market players, and investors to determine emerging economies. These insights offered in the report would benefit market players to formulate strategies for the future and gain a strong position in the global market.

A summary of the performance evaluation of the Pharmacogenomics Market is offered in this report. It also includes crucial information concerning to the key industry trends and projected growth rate of the said market. The study provides details regarding the growth avenues and hindering factors prevailing in the business space.

Asia Pacific pharmacogenomics market will grow by 10.3% annually with a total addressable market cap of $21.7 billion over 2020-2030 owing to the rising adoption of personalized medicine and usage of pharmacogenomics for drug discovery and development amid COVID-19 pandemic.

Highlighted with 35 tables and 49 figures, this 122-page report Asia Pacific Pharmacogenomics Market 2020-2030 by Service (Genotyping, SNP, Diagnostics), Technology (PCR, Microarray, Sequencing, Electrophoresis, MS), Application, End User, and Country: Trend Forecast and Growth Opportunity is based on a comprehensive research of the entire Asia Pacific pharmacogenomics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects: Market Structure Growth Drivers Restraints and Challenges Emerging Product Trends & Market Opportunities Porters Fiver ForcesThe trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmacogenomics market in every aspect of the classification from perspectives of Service, Technology, Application, End User, and Country.

Based on Service, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Genotyping SNP Identification Diagnostics Other Services

Based on Technology, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Polymerase Chain Reaction (PCR) Microarray Sequencing Electrophoresis Mass Spectrometry Other Technologies

Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Oncology Infectious Diseases Neurology/Psychiatry Cardiovascular Pain Management Other Applications

Based on End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. Hospitals and Clinics Pharmaceutical Companies Research Institutes

Geographically, the following national/local markets are fully investigated: Japan China South Korea Australia India Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)Detailed analysis and annual revenue 2019-2030 are available for each key national market. The breakdown of key national markets by Service, Technology, and Application over the forecast years are also included.The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.Specifically, potential risks associated with investing in Asia Pacific pharmacogenomics market are assayed quantitatively and qualitatively through SDMRs Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.Key Players (this may not be a complete list and extra companies can be added upon request):23andMe, Inc.Abbott LaboratoriesAdmera Health, LLCAgena Biosciences, Inc.Astra Zeneca PLCBayer AGBecton, Dickinson and CompanyCancer Genetics, Inc.Dynamic DNA LaboratoriesEmpire Genomics LLCF. Hoffmann-La Roche LtdgeneOmbio Technologies Pvt Ltd.Genomic Health, Inc.Illumina, Inc.Laboratory Corporation of America HoldingsMyriad Genetics Inc.Oneome LLCOpko Health, Inc.Pathway Genomics CorporationQIAGEN N.V.Quest Diagnostics IncorporatedTeva Pharmaceuticals Industries Ltd.Thermo Fisher Scientific Inc.Transgenomic, Inc.(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

Get More Information About Full Report/Talk to our Analyst Regarding Pharmacogenomics Market @https://www.supplydemandmarketresearch.com/home/contact/1508770?ref=Discount&toccode=SDMRHE1508770

This comprehensive report can be a guideline for the industry stakeholders that helps in analyzing the Pharmacogenomics Market and forecast of till 2024. This report aids to detection of the projected market size, market status, future predictions, growth prospect, main challenges of Pharmacogenomics Market by analyzing the segmentations.

In the following section, the report provides the Pharmacogenomics Market company outline, statements of the product, and performance values. With the support of the arithmetical study, the report demonstrates the complete international Pharmacogenomics Market market inclusive of amplitude, production, manufacturing value, loss/gain, Pharmacogenomics Market supply/demand and import/export. The Pharmacogenomics Market report is divided into key companies, by regions, and by various sectors such as application, type for the competitive landscape analyze.

About Us:

We have a strong network of high powered and experienced global consultants who have about 10+ years of experience in the specific industry to deliver quality research and analysis. Having such an experienced network, our services not only cater to the client who wants the basic reference of market numbers and related high growth areas in the demand side, but also we provide detailed and granular information using which the client can definitely plan the strategies with respect to both supply and demand side.

Contact Us:

SUPPLY DEMAND MARKET RESEARCH

Mr. Charles Lee

302-20 Misssisauga Valley Blvd, Missisauga,

L5A 3S1, Toronto, Canada

Phone Number: +12764775910

Email- [emailprotected]

See the original post:
Pharmacogenomics Market To Witness Robust Expansion Throughout The Forecast Period 2020- 2027 - The Daily Chronicle